


Accepted Manuscript

Preclinical profile of a dopamine D1 potentiator suggests therapeutic utility in neurological and psychiatric disorders

Robert F. Bruns, Stephen N. Mitchell, Keith A. Wafford, Alex J. Harper, Elaine A. Shanks, Guy Carter, Michael J. O'Neill, Tracey K. Murray, Brian J. Eastwood, John M. Schaus, James P. Beck, Junliang Hao, Jeffrey M. Witkin, Xia Li, Eyassu Chernet, Jason S. Katner, Hong Wang, John W. Ryder, Meghane E. Masquelin, Linda K. Thompson, Patrick L. Love, Deanna L. Maren, Julie F. Falcone, Michelle M. Menezes, Linli Zhang, Charles R. Yang, Kjell A. Svensson



PII: S0028-3908(17)30499-9

DOI: [10.1016/j.neuropharm.2017.10.032](https://doi.org/10.1016/j.neuropharm.2017.10.032)

Reference: NP 6917

To appear in: *Neuropharmacology*

Received Date: 21 April 2017

Revised Date: 24 August 2017

Accepted Date: 24 October 2017

Please cite this article as: Bruns, R.F., Mitchell, S.N., Wafford, K.A., Harper, A.J., Shanks, E.A., Carter, G., O'Neill, M.J., Murray, T.K., Eastwood, B.J., Schaus, J.M., Beck, J.P., Hao, J., Witkin, J.M., Li, X., Chernet, E., Katner, J.S., Wang, H., Ryder, J.W., Masquelin, M.E., Thompson, L.K., Love, P.L., Maren, D.L., Falcone, J.F., Menezes, M.M., Zhang, L., Yang, C.R., Svensson, K.A., Preclinical profile of a dopamine D1 potentiator suggests therapeutic utility in neurological and psychiatric disorders, *Neuropharmacology* (2017), doi: 10.1016/j.neuropharm.2017.10.032.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Preclinical Profile of a Dopamine D1 Potentiator Suggests Therapeutic Utility in Neurological and Psychiatric Disorders

Robert F Bruns¹, Stephen N Mitchell², Keith A Wafford², Alex J Harper², Elaine A Shanks², Guy Carter², Michael J O'Neill², Tracey K Murray², Brian J Eastwood², John M Schaus¹, James P Beck¹, Junliang Hao¹, Jeffrey M Witkin¹, Xia Li¹, Eyassu Chernet¹, Jason S Katner¹, Hong Wang¹, John W Ryder¹, Meghane E Masquelin¹, Linda K. Thompson¹, Patrick L. Love¹, Deanna L Maren¹, Julie F Falcone¹, Michelle M Menezes¹, Linli Zhang³, Charles R Yang³, and Kjell A Svensson¹

¹Lilly Research Laboratories, Eli Lilly & Co., Lilly Corporate Center, Indianapolis, IN 46285, USA

²Lilly Research Laboratories, Eli Lilly & Co., Erl Wood Manor, United Kingdom

³Shanghai ChemPartner, Pudong, Shanghai, China, 201203

Address correspondence to: Dr. Kjell A. Svensson, Lilly Research Laboratories, Eli Lilly & Co., Lilly Corporate Center, Indianapolis, IN 46033, USA. 317 433-1889. E-mail: svensson_kjell_a@lilly.com.

Footnotes

¹Abbreviations: CREB, cyclic AMP response element binding protein; DETQ, 2-(2,6-dichlorophenyl)-1-((1S,3R)-3-(hydroxymethyl)-5-(2-hydroxypropan-2-yl)-1-methyl-3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-one; hD1 mouse: human D1 knock-in mouse; GluR1, ionotropic glutamate receptor 1; LMA, locomotor activity; PAM, positive allosteric modulator;

Download English Version:

<https://daneshyari.com/en/article/8517552>

Download Persian Version:

<https://daneshyari.com/article/8517552>

[Daneshyari.com](https://daneshyari.com)